Core Viewpoint - The article emphasizes the urgent need for improved cancer prevention and treatment strategies in China, particularly focusing on liver cancer, which poses significant challenges due to late diagnosis, limited treatment options, and high recurrence rates [1][2]. Group 1: Challenges in Liver Cancer Treatment - Current challenges in liver cancer diagnosis and treatment include late diagnosis, limited treatment methods, and high postoperative recurrence rates [2] - Traditional screening methods have low sensitivity for detecting liver cancer smaller than 1 cm, leading to high rates of missed early diagnoses [2] - Approximately 90% of liver cancer patients in China are related to hepatitis B virus infection, highlighting the need for better vaccination and antiviral treatment [2] - There is a lack of public awareness regarding the "silent organ" nature of liver cancer, resulting in weak screening awareness among high-risk populations [2]. Group 2: Research Breakthroughs - The TIMES model, developed by Liu Lianxin's team, is a new immune scoring system that predicts postoperative recurrence risk based on tumor microenvironment heterogeneity [3] - This model utilizes five key indicators, including NK cell distribution, and incorporates artificial intelligence to guide immunotherapy decisions [3] - The research also identifies "immune desert" areas in the tumor microenvironment, where SPP1-positive macrophages inhibit immune cell activity, leading to the development of small molecule compounds and antibody drugs to enhance immunotherapy response [3]. Group 3: Technological Innovations - The use of AI imaging recognition systems and screening applications at Mengchao Hepatobiliary Hospital has improved early liver cancer detection rates [4] - A population screening project in Fujian Province has covered 2.3 million people, diagnosing 2,029 liver cancer cases and initiating interventions [4] - Advanced surgical techniques, including 3D reconstruction and fluorescence navigation, have significantly improved the precision and safety of laparoscopic liver resections, reducing postoperative complication rates [4] - AI-assisted systems are integrated throughout the entire "screen-diagnose-treat-recover" cycle, enhancing personalized follow-up and dynamic quality control, with patient compliance increasing by over 30% [4] - The advancements in liver cancer treatment position China among the global leaders, with significant achievements in surgical, interventional, and combined immunotherapy [4].